Oridonin ring A-based diverse constructions of enone functionality: Identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis

Journal of Medicinal Chemistry

Volumn 56, Issue 21, 2013, Pages 8814-8825

  Ding, Chunyong ^a   Zhang, Yusong ^b,c   Chen, Haijun ^a   Yang, Zhengduo ^c   Wild, Christopher ^a   Ye, Na ^a   Ester, Corbin D ^c   Xiong, Ailian ^c   White, Mark A ^a   Shen, Qiang ^c   Zhou, Jia ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 [(DIMETHYLAMINO)METHYLENE] 7 HYDROXY 5,5,8,8 TETRAMETHYL 15-METHYLENEOCTAHYDRO 1H 6A,11A (EPOXYMETHANO) 3,3A 1 ETHANOPHENANTHRO[1,10 DE][1,3]DIOXINE 11,14(2H) DIONE; 5,14 DIHYDROXY 2 (HYDROXYMETHYLENE) 4,4 DIMETHYL 8 METHYLENEOCTAHYDRO 1H 3,11B (EPOXYMETHANO) 6A,9 METHANOCYCLOHEPTA[A]NAPHTHALENE 1,6,7(2H,8H) TRIONE; 5,14 DIHYDROXY 2 (METHOXYMETHYLENE) 4,4 DIMETHYL 8 METHYLENEOCTAHYDRO 1H 3,11B (EPOXYMETHANO) 6A,9 METHANOCYCLOHEPTA[A]NAPHTHALENE 1,6,7(2H,8H) TRIONE; 5,6,14 TRIHYDROXY 4,4 DIMETHYL 8 METHYLENE 4,4A,5,6,9,10,11,11A OCTAHYDRO 1H 6,11B (EPOXYMETHANO) 6A,9 MERTHANOCYCLOHEPA[A]NAPHTHALENE 1,7(8H) DIONE; 5,6,14 TRIHYDROXY 4,4 DIMETHYL 8 METHYLENE 4,4A,5,6,9,10,11,11A OCTAHYDRO 3H 6,11B (EPOXYMETHANO) 6A,9 METHANOCYCLOHEPTA[A]NAPHTHALENE 3,7(8H) DIONE; 7 HYDROXY 10 (HYDROXYMETHYLENE) 5,5,8,8 TETRAMETHYL 15 METHYLENEOCTAHYDRO 1H 6A,11A (EPOXYMETHANO) 3,3A 1 ETHANOPHENANTHRO[1,10 DE][1,3]DIOXINE 11,14(2H) DIONE; 7 HYDROXY 5,5,8,8 TETRAMETHYL 15 METHYLENE 11,14 DIOXO 2,3,3A,7,7A,8,11,11B OCTAHYDRO 1H 6A,11A (EPOXYMETHANO) 3,3A 1 ETHANOPHENANTHRO[1,10 DE][1,3]DIOXINE 10 CARBALDEHYDE; 7 HYDROXY 5,5,8,8 TETRAMETHYL 15 METHYLENE 14 OXODECAHYDRO 1H 6A,11A (EPOXYMETHANO) 3,3A 1 ETHANOPHENANTHRO[1,10 DE][1,3]DIOXIN 11 YL METHANESULFONATE; 7 HYDROXY 5,5,8,8 TETRAMETHYL 15 METHYLENE 2,3,3A,7,7A,8,9,11B OCTAHYDRO 1H 6A,11A (EPOXYMETHANO) 3,3A 1 ETHANOPHENANTHRO[1,10 DE][1,3]DIOXIN 14 ONE; 7 HYDROXY 5,5,8,8 TETRAMETHYL 15 METHYLENE 3,3A,7,7A,8,11B HEXAHYDRO 1H 6A,11A (EPOXYMETHANO) 3,3A 1 ETHANOPHENANTHRO[1,10 DE][1,3]DIOXINE 11,14(2H) DIONE; 7 HYDROXY 5,5,8,8 TETRAMETHYL 15 METHYLENE 3,3A,7,7A,8,11B HEXAHYDRO 1H 6A,11A (EPOXYMETHANO) 3,3A 1 ETHANOPHENANTHRO[1,10 DE][1,3]DIOXINE 9,14(2H) DIONE; 7,9 DIHYDROXY 5,5,8,8 TETRAMETHYL 15 METHYLENE 2,3,3A,7,7A,8,9,11B OCTAHYDRO 1H 6A,11A (EPOXYMETHANO) 3,3A 1 ETHANOPHENANTHRO[1,10 DE][1,3]DIOXIN 14 ONE; ANTINEOPLASTIC AGENT; DIENONE DERIVATIVE; KETONE DERIVATIVE; ORIDONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST EPITHELIUM; BROMINATION; CANCER CELL CULTURE; CELL GROWTH; COLONY FORMATION; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; ELECTROPHILICITY; ELIMINATION REACTION; FEMALE; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; MICHAEL ADDITION; MOUSE; NONHUMAN; NUCLEOPHILICITY; REACTION ANALYSIS; REACTION TIME; STEREOCHEMISTRY; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DITERPENES, KAURANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EPITHELIAL CELLS; FEMALE; HUMANS; MCF-7 CELLS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84887892414     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401248x     Document Type: Article

References (58)

1. Fernández, Y.; Cueva, J.; Palomo, A. G.; Ramos, M.; de Juan, A.; Calvo, L.; Garcia-Mata, J.; Garcia-Teijido, P.; Peláez, I.; Garcia-Estevez, L. Novel therapeutic approaches to the treatment of metastatic breast cancer Cancer Treat. Rev. 2010, 36, 33-42
2. Beaumont, T.; Leadbeater, M. Treatment and care of patients with metastatic breast cancer Nurs. Stand. 2011, 25, 49-56
3. Hudis, C. A.; Gianni, L. Triple-negative breast cancer: an unmet medical need Oncologist 2011, 16 (Suppl. 1) 1-11
4. McAllister, S. D.; Murase, R.; Christian, R. T.; Lau, D.; Zielinski, A. J.; Allison, J.; Almanza, C.; Pakdel, A.; Lee, J.; Limbad, C.; Liu, Y.; Debs, R. J.; Moore, D. H.; Desprez, P. Y. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis Breast Cancer Res. Treat. 2011, 129, 37-47
5. Simstein, R.; Burow, M.; Parker, A.; Weldon, C.; Beckman, B. Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system Exp. Biol. Med. (Maywood, NJ, U. S.) 2003, 228, 995-1003
6. Liu, Y. Y.; Yu, J. Y.; Yin, D.; Patwardhan, G. A.; Gupta, V.; Hirabayashi, Y.; Holleran, W. M.; Giuliano, A. E.; Jazwinski, S. M.; Gouaze-Andersson, V.; Consoli, D. P.; Cabot, M. C. A role for ceramide in driving cancer cell resistance to doxorubicin FASEB J. 2008, 22, 2541-2551
7. Vuorelaa, P.; Leinonenb, M.; Saikkuc, P.; Tammelaa, P.; Rauhad, J. P.; Wennberge, T.; Vuorela, H. Natural products in the process of finding new drug candidates Curr. Med. Chem. 2004, 11, 1375-1389
8. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010 J. Nat. Prod. 2012, 75, 311-335
9. Fujita, E.; Nagao, Y.; Kaneko, K.; Nakazawa, S.; Kuroda, H. The antitumor and antibacterial activity of the Isodon diterpenoids Chem. Pharm. Bull. 1976, 24, 2118-2127
10. Fujita, E.; Nagao, Y.; Kohno, T.; Matsuda, M.; Ozaki, M. Antitumor activity of acylated oridonin Chem. Pharm. Bull. 1981, 29, 3208-3213
11. Li, B.; Li, N.; Wang, S.; Gao, J.; Fang, S. Pharmacokinetics of injectable beta-cyclodetrin inclusion complex in Wistar rats Int. J. Pharm. Pharm. Sci. 2012, 4, 92-95
12. Yin, F.; Liang, J. Y.; Liu, J. Chemical constitutes of "Dong ling cao" J. Chin. Pharm. Univ. 2003, 34, 302-304
13. Guan, Y. Z.; Wei, T. H. Clinical research on the oridonin injection for the interventional therapy of liver cancer J. Med. Radiol. Technol. 2005, 236, 43-45
14. Wang, R. L. Clinical evaluation of Rabdosia rubescences for 31 patients with liver cancer Chin. J. Cancer 1984, 8, 50-52
15. Henan Research Group for Rabdosia Rubescences. Conclusion of clinical evaluation of Rabdosia rubescences for the treatment of 68 patients with esophageal carcinoma and carcinoma of gastric cardia Cancer Res. Prev. Treat. 1976, 3, 32-33
16. Li, C.; Wang, E.; Cheng, Y.; Bao, J. Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics Int. J. Biochem. Cell Biol. 2011, 43, 701-704
17. Hsieh, T. C.; Wijeratne, E. K.; Liang, J. Y.; Gunatilaka, A. L.; Wu, J. M. Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens Biochem. Biophys. Res. Commun. 2005, 337, 224-231
18. Zhang, Y.; Wu, Y.; Wu, D.; Tashiro, S.; Onodera, S.; Ikejima, T. NF-kappab facilitates oridonin-induced apoptosis and autophagy in HT1080 cells through a p53-mediated pathway Arch. Biochem. Biophys. 2009, 489, 25-33
19. Ding, C.; Zhang, Y.; Chen, H.; Yang, Z.; Wild, C.; Chu, L.; Liu, H.; Shen, Q.; Zhou, J. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility J. Med. Chem. 2013, 56, 5048-5058
20. Ding, C.; Zhang, Y.; Chen, H.; Wild, C.; Wang, T.; White, M. A.; Shen, Q.; Zhou, J. Overcoming synthetic challenges of oridonin A-ring structural diversification: regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position Org. Lett. 2013, 15, 3718-3721
21. Zhang, W.; Huang, Q.; Hua, Z. Oridonin: a promising anticancer drug from China Front. Biol. 2010, 5, 540-545
22. Niu, X. M.; Li, S. H.; Li, M. L.; Zhao, Q. S.; Mei, S. X.; Na, Z.; Wang, S. J.; Lin, Z. W.; Sun, H. D. Cytotoxic ent-kaurane diterpenoids from Isodon eriocalyx var. laxiflora Planta Med. 2002, 68, 528-533
23. Wang, L.; Zhao, W. L; Yan, J. S; Liu, P.; Sun, H. P.; Zhou, G. B.; Weng, Z. Y.; Wu, W. L.; Weng, X. Q.; Sun, X. J; Chen, Z.; Sun, H. D.; Chen, S. J. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner Cell Death Differ. 2007, 14, 306-317
24. Festa, C.; Lauro, G.; De Marino, S.; D'Auria, M. V.; Monti, M. C.; Casapullo, A.; D'Amore, C.; Renga, B.; Mencarelli, A.; Petek, S.; Bifulco, G.; Fiorucci, S.; Zampella, A. Plakilactones from the marine sponge Plakinastrella mamillaris. Discovery of a new class of marine ligands of peroxisome proliferator-activated receptor γ J. Med. Chem. 2012, 55, 8303-8317
25. Honda, T.; Rounds, B. V.; Bore, L.; Finlay, H. J.; Favaloro, F.; Suh, N.; Wang, Y.; Sporn, M. B.; Gribble, G. W. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages J. Med. Chem. 2000, 43, 4233-4246
26. Liby, K. T.; Yore, M. M.; Sporn, M. B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer Nat. Rev. Cancer 2007, 7, 357-369
27. Pergola, P. E.; Raskin, P.; Toto, R. D.; Meyer, C. J.; Huff, J. W.; Grossman, E. B.; Krauth, M.; Ruiz, S.; Audhya, P.; Christ-Schmidt, H.; Wittes, J.; Warnock, D. G. Bardoxolone methyl and kidney function in CKD with type 2 diabetes N. Engl. J. Med. 2011, 365, 327-336
28. Lorusso, D.; Mainenti, S.; Pietragalla, A.; Ferrandina, G.; Foco, G.; Masciullo, V.; Scambia, G. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity Expert Opin. Invest. Drugs 2009, 18, 1939-1946
29. Shiraki, T.; Kamiya, N.; Shiki, S.; Kodama, T. S.; Kakizuka, A.; Jingami, H. Alpha,beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma J. Biol. Chem. 2005, 280, 14145-14153
30. Straus, D. S.; Glass, C. K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets Med. Res. Rev. 2001, 21, 185-210
31. Gayarre, J.; Stamatakis, K.; Renedo, M.; Perez-Sala, D. Differential selectivity of protein modification by the cyclopentenone prostaglandins PGA1 and 15-deoxy-Delta12,14-PGJ2: role of glutathione FEBS Lett. 2005, 579, 5803-5808
32. Ricote, M.; Li, A. C.; Willson, T. M.; Kelly, C. J.; Glass, C. K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 1998, 391, 79-82
33. Das, U.; Sharma, R. K.; Dimmock, J. R. 1,5-Diaryl-3-oxo-1,4-pentadienes: a case for antineoplastics with multiple targets Curr. Med. Chem. 2009, 16, 2001-2020
34. Mutus, B.; Wagner, J. D.; Talpas, C. J.; Dimmock, J. R.; Phillips, O. A.; Reid, R. S. 1- p -Chlorophenyl-4,4-dimethyl-5-diethylamino-1-penten-3-one hydrobromide, a sulfhydryl-specific compound which reacts irreversibly with protein thiols but reversibly with small molecular weight thiols Anal. Biochem. 1989, 177, 237-243
35. Lee, K. H.; Huang, E. S.; Piantadosi, C.; Pagano, J. S.; Geissman, T. A. Cytotoxicity of sesquiterpene lactones Cancer Res. 1971, 31, 1649-1654
36. Lee, K. H.; Hall, I. H.; Mar, E. C.; Starnes, C. O.; El Gebaly, S. A.; Waddell, T. G.; Hadgraft, R. I.; Ruffner, C. G.; Weidner, I. Sesquiterpene antitumor agents: inhibitors of cellular metabolism Science 1977, 196, 533-536
37. Benvenuto, J. A.; Connor, T. H.; Monteith, D. K.; Laidlaw, J. A.; Adams, S. C.; Matney, T. S.; Theiss, J. C. Degradation and inactivation of antitumor drugs J. Pharm. Sci. 1993, 82, 988-991
38. Ohori, H.; Yamakoshi, H.; Tomizawa, M.; Shibuya, M.; Kakudo, Y.; Takahasji, A.; Takahashi, S.; Kato, S.; Suzuki, T.; Ishioka, C.; Iwabuchi, Y.; Shibata, H. Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer Mol. Cancer Ther. 2006, 5, 2563-2571
39. Dimmock, J. R.; Raghavan, S. K.; Logan, B. M.; Bigam, G. E. Antileukemic evaluation of some Mannich bases derived from 2-arylidene-1,3-diketones Eur. J. Med. Chem. 1983, 18, 248-254
40. Chen, G.; Waxman, D. J. Role of cellular glutathione and glutathione S -transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells Biochem. Pharmacol. 1994, 47, 1079-1087
41. Zhou, W.; Cheng, Y. The chemoselective synthesis for eriocalyxin B and its analogues Acta Chim. Sin. 1990, 48, 1185-1190
42. Reich, H. J.; Renga, J. M.; Reich, I. L. Organoselenium chemistry. Conversion of ketones to enones by selenoxide syn -elimination J. Am. Chem. Soc. 1975, 97, 5434-5447
43. Nicolaou, K. C.; Monagnon, T.; Baran, P. S.; Zhong, Y. L. Iodine(V) reagents in organic synthesis. Part 4. o -Iodoxybenzoic acid as a chemospecific tool for single electron transfer-based oxidation processes J. Am. Chem. Soc. 2002, 124, 2245-2258
44. Chai, K. B.; Sampson, P. Macrolactonization-transannular aldol condensation approach to the taxane AB ring system J. Org. Chem. 1993, 58, 6807-6813
45. Takahito, I.; Kyoko, T.; Takahiro, U.; Masataka, K.; Norimitsu, T.; Mikiji, M. Topochemical reaction of 7-bromoethoxycarbonyl-7-cyano-1,4- benzoquinone methide in the solid state Chem. Lett. 2006, 35, 918-919
46. Henschler, D.; Eder, E. Structure-activity relationships of alpha, beta-unsaturated carbonylic compounds IARC Sci. Publ. 1986, 70, 197-205
47. Rosen, J. D.; Segall, Y.; Casida, J. E. Mutagenic potency of haloacroleins and related compounds Mutat. Res. 1980, 78, 113-119
48. Verbitski, S. M.; Mullally, J. E.; Fitzpatrick, F. A.; Ireland, C. M. Punaglandins, chlorinated prostaglandins, function as potent Michael receptors to inhibit ubiquitin isopeptidase activity J. Med. Chem. 2004, 47, 2062-2070
49. Basavaiah, D.; Rao, A. J.; Satyanarayana, T. Recent advances in the Baylis-Hillman reaction and applications Chem. Rev. 2003, 103, 811-892
50. Ito, H.; Takenaka, Y.; Fukunishi, S.; Iguchi, K. A practical preparation of 2-hydroxymethyl-2-cyclopenten-1-one by Morita-Baylis-Hillman reaction Synthesis 2005, 18, 3035-3038
51. Liotta, D.; Barnum, C.; Puleo, R.; Zima, G.; Bayer, C.; Kezar, H. S., III. A simple method for the efficient sysnthesis of unsaturated β-dicarbonyl compunds J. Org. Chem. 1981, 46, 2920-2923
52. CCDC 919314 (13) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data-request/cif.
53. Jana, C. K.; Hoecker, J.; Woods, T. M.; Jessen, H. J.; Neuburger, M.; Gademann, K. Synthesis of withanolide A, biological evaluation of its neuritogenic properties, and studies on secretase inhibition Angew. Chem., Int. Ed. 2011, 50, 8407-8411
54. Wharton, P. S.; Bohlen, D. H. Hydrazine reduction of α,β-epoxy ketones to allylic alcohols J. Org. Chem. 1961, 26, 3615-3616
55. Muller, R.; Ruedi, P. An unexpected (3→2)-hydride shift in phyllocladane (=13β-kaurane) diterpenoids and in related trimethyl-substituted bi- and tricyclic compounds Helv. Chim. Acta 2003, 86, 439-456
56. Hirai, S.; Nakada, M. An enantioselective approach to (-)-platencin via catalytic asymmetric intramolecular cyclopropanation Tetrahedron Lett. 2010, 51, 5076-5079
57. Zhang, C. L.; Wu, L. J.; Tashiro, S.; Onodera, S.; Ikejima, T. Oridonin induces a caspase-independent but mitochondria- and MAPK-dependent cell death in the murine fibrosarcoma cell line L929 Biol. Pharm. Bull. 2004, 27, 1527-1531
58. Chen, S.; Gao, J.; Halicka, H. D.; Huang, X.; Traganos, F.; Darzynkiewicz, Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage Int. J. Oncol. 2005, 26, 579-588